GYRE
HEALTHCAREGyre Therapeutics Inc
Live · NASDAQ · May 9, Close
What's Moving GYRE Today?
No stock-specific AI insight has been generated for GYRE yet. Check back soon — insights are generated from recent news analysis.
52-Week Range
$8.04
Fundamentals
Trading
GYRE News
23 articles- Gyre Therapeutics (GYRE) CSO discloses new Series B stakeStock Titan·May 8, 2026
- Gyre Therapeutics (GYRE) EVP details multiple stock option grantsStock Titan·May 8, 2026
- Gyre Therapeutics (GYRE) GC holds option for 47,530 sharesStock Titan·May 8, 2026
- Gyre Therapeutics, Inc. (GYRE) Reports Q1 Loss, Lags Revenue EstimatesYahoo Finance·May 7, 2026
- Gyre Therapeutics Reports First Quarter 2026 Results and Provides Business UpdateYahoo Finance·May 7, 2026
- Gyre Therapeutics Completes Acquisition of Cullgen to Create U.S.- and China-based Fully Integrated Biopharmaceutical CompanyYahoo Finance·May 4, 2026
- US High Growth Tech Stocks To WatchYahoo Finance·Apr 27, 2026
- Exploring Three High Growth Tech Stocks In The US MarketYahoo Finance·Mar 27, 2026
- Gyre Therapeutics Announces China’s NMPA Grants Priority Review to the NDA for Hydronidone (F351) for CHB-Induced Liver Fibrosis TreatmentYahoo Finance·Mar 17, 2026
- Gyre Therapeutics, Inc. (GYRE) Q4 Earnings Miss EstimatesYahoo Finance·Mar 12, 2026
- Gyre Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business UpdateYahoo Finance·Mar 12, 2026
- Voyager Therapeutics (VYGR) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Mar 9, 2026
- Gyre Therapeutics to acquire Cullgen in $300M all-stock transactionYahoo Finance·Mar 3, 2026
- Sector Update: Health Care Stocks Retreat Late AfternoonYahoo Finance·Mar 2, 2026
- Gyre Therapeutics Enters into Agreement to Acquire Cullgen to Gain Targeted Protein Degradation Platform and PipelineYahoo Finance·Mar 2, 2026
- Day One Biopharmaceuticals, Inc. (DAWN) Reports Q4 Loss, Beats Revenue EstimatesYahoo Finance·Feb 25, 2026
- High Growth Tech Stocks in US for February 2026Yahoo Finance·Feb 11, 2026
- Discovering Undiscovered Gems in the US MarketYahoo Finance·Jan 26, 2026
- High Growth Tech Stocks To Watch In The US Market January 2026Yahoo Finance·Jan 13, 2026
- Gyre Therapeutics Announces Alignment with China’s CDE on Conditional Approval Pathway and Priority Review Eligibility for Hydronidone Following Pre-NDA MeetingYahoo Finance·Jan 5, 2026
- Undiscovered Gems in the US Market to Explore This December 2025Yahoo Finance·Dec 26, 2025
- Exploring High Growth Tech Stocks in the US MarketYahoo Finance·Nov 14, 2025
- We Think That There Are Issues Underlying Gyre Therapeutics' (NASDAQ:GYRE) EarningsYahoo Finance·Nov 14, 2025
All 23 articles loaded
Price Data
52-Week Range
$8.04
Fundamentals
Trading
About Gyre Therapeutics Inc
Gyre Therapeutics Inc. is a cutting-edge biopharmaceutical company dedicated to developing innovative therapies for rare and complex diseases. By utilizing a proprietary platform, Gyre accelerates the discovery and commercialization of precision treatments aimed at addressing significant unmet medical needs. The company's strong focus on scientific excellence and patient-centered outcomes, coupled with its advancing pipeline in gene therapy and precision medicine, positions Gyre for substantial growth within the competitive biopharmaceutical landscape. Through strategic partnerships and a commitment to research, Gyre is poised to make a meaningful impact on the lives of patients facing challenging health conditions.